Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience

• Published in: Journal of gastrointestinal cancer Vol. 48; no. 3; p. 281
• Main Authors: İnce, Semra, Karaman, Bülent, Alagoz, Engin, Karadurmuş, Nuri, Şan, Hüseyin, Erçin, Cemal Nuri, Arslan, Nuri
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York Springer US 01.09.2017
• Subjects: Abstract; Cancer Research; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - radiotherapy; Female; Gastroenterology; Humans; Internal Medicine; Liver Neoplasms - pathology; Liver Neoplasms - radiotherapy; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Radiotherapy; Yttrium Radioisotopes - therapeutic use
• ISSN: 1941-6628; 1941-6636
• DOI: 10.1007/s12029-017-9968-z

Background/Aim Selective intraarterial radionuclide therapy (SIRT) with yttrium-90 (Y-90) resin microspheres presently has successful results in primary or metastatic inoperable liver tumors. This procedure, which is also known as radioembolisation, delivers high doses of radiation selectively to hepatic tumors while minimum healthy liver exposure. The aim of this study was to present our clinical experience of radiomicrosphere therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Methods We performed 40 Y-90 microsphere therapies in 28 patients (5 females, 23 males; mean age ± SD 48 ± 8) with HCC during the period from April 2008 through December 2016. Pretreatment Tc-99m microaggregated albumin (MAA) scintigraphy was performed to all patients in order to detect eligibility for SIRT. All patients had pre- and post-biochemical tests (hemogram and serologic tests) and imaging methods (CT or MRI or PET/CT) at regular intervals to detect any possible complication and determine response rates. Results The mean shunting to the lungs on MAA scan was 6.5% and the mean ± SD administered dose of Y-90 was 1.55 ± 0.32 GBq in all patients. The estimated doses to the target tumors, normal liver parenchyma and lungs were 105.7 ± 55.3, 25.5 ± 8.2 and 5.8 ± 1.7 Gy, respectively. No significant complication was observed during or early after (first week) the treatment procedure and it was well tolerated by all the patients. Only one patient developed a treatment-related gastroduodenal ulcer 3 weeks after the treatment. In control imaging tests (MRI or FDG PET/CT) performed 2.5 months after the treatment, we observed complete response in 2 (7%) patients, partial response in 10 (36%) patients, stable disease in 5 (18%) patients and progressive disease in 11 (39%) patients. Conclusion According to our clinical experience, we can conclude that Y-90 microsphere therapy is a safe and effective treatment option for the patients with unresectable HCC without any serious side effects.